Phenotypes Associated with This Genotype

Genotype
MGI:3718360

• Allelic Composition: Mapt^tm1Hnd/Mapt^tm1Hnd; Zbtb20^{Tg(PDGFB-APPSwInd)20Lms}/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

behavior/neurological phenotype ( J:121330 )

N • mice show normal spatial learning and object-recongition memory, at levels similar to non-transgenic controls

N • mice show no signs of hyperactivity

decreased susceptibility to pharmacologically induced seizures ( J:121330 )

• seizures are less severe and occur at longer latencies compared to transgenic mice with wild-type Mapt

nervous system

decreased susceptibility to pharmacologically induced seizures ( J:121330 )

• seizures are less severe and occur at longer latencies compared to transgenic mice with wild-type Mapt

amyloid beta deposits ( J:121330 )

• at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous or wild-type for Mapt

abnormal neuron morphology ( J:121330 )

• mice show neuritic dystrophy around amyloid plaques

abnormal neuron differentiation ( J:121330 )

• aberrant sprouting of hippocampal axons is observed in transgenic mice

cellular

abnormal neuron differentiation ( J:121330 )

• aberrant sprouting of hippocampal axons is observed in transgenic mice

homeostasis/metabolism

amyloid beta deposits ( J:121330 )

• at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous or wild-type for Mapt